Treatment of actinic keratoses with 5% topical imiquimod: A multicenter prospective observational study from 93 Austrian office-based dermatologists

Journal of Drugs in Dermatology

Volumn 11, Issue 5, 2012, Pages 574-578

  Strohal, Robert ^a   Kerl, Helmut ^b   Schuster, Lydia ^c  

^a Federal Academic Teaching Hospital   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Meda Pharma   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; EMOLLIENT AGENT; IMIQUIMOD; IMMUNOSUPPRESSIVE AGENT; STEROID;

ACTINIC KERATOSIS; AGED; ARTICLE; AUSTRIA; CONTROLLED STUDY; CREAM; CRYOSURGERY; DERMATOLOGIST; DIZZINESS; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FACE INJURY; FEMALE; FEVER; HEADACHE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; MEDICAL HISTORY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT PARTICIPATION; PATIENT SATISFACTION; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SHIVERING; SKIN BURNING SENSATION; STANDARDIZATION; TREATMENT OUTCOME; WEAKNESS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; AUSTRIA; DERMATOLOGY; FEMALE; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860891901     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Szeimies RM, Gerritsen MJP, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004;51:547-555. (Pubitemid 39278073)
2. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50:714-721. (Pubitemid 38580548)
3. Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Brit J Dermatol. 2007;157:133-141. (Pubitemid 46934262)
4. Jorizzo J, Dinehart S, Matheson R. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week on one or two courses of treatment of actinic keratoses on the head. J Am Acad Dermatol. 2007;57:1-4.
5. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. J Am Acad Dermatol. 2002;47:1-9.
6. Stockfleth E, Sterry W, Carey-Yard M, et al. Multicentre, open-label study using Imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Brit J Dermatol. 2007;157:41-46. (Pubitemid 350179629)
7. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids -new mechanisms for old drugs. N Engl J Med. 2005;353:1711-1723.
8. Murphy K, Travers P, Walport M. In: Janeway's Immunobiology. New York: Garland Science, Taylor & Francis Group, 2008;656-658.
9. Hurwitz DH, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol. 2003;139:1347-1350. (Pubitemid 37248285)
10. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Intern J Dermatol. 2006;45:489-498.
11. Schiessl C, Wolber C, Tauber M, et al. Treatment of all basal cell carcinoma variants including large and high risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, follow up. J Drugs Dermatol. 2007;6:507-513.